🇺🇸 elvitegravir/cobicistat/emtricitabine/tenofovir in United States

219 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Maternal Exposure During Pregnancy — 46 reports (21%)
  2. Foetal Exposure During Pregnancy — 28 reports (12.79%)
  3. Abortion Spontaneous — 23 reports (10.5%)
  4. Product Use Issue — 23 reports (10.5%)
  5. Off Label Use — 21 reports (9.59%)
  6. Pneumonia — 20 reports (9.13%)
  7. Cerebrovascular Accident — 19 reports (8.68%)
  8. Death — 14 reports (6.39%)
  9. Neoplasm Malignant — 14 reports (6.39%)
  10. Weight Increased — 11 reports (5.02%)

Source database →

Other Infectious Disease / Virology approved in United States

Frequently asked questions

Is elvitegravir/cobicistat/emtricitabine/tenofovir approved in United States?

elvitegravir/cobicistat/emtricitabine/tenofovir does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for elvitegravir/cobicistat/emtricitabine/tenofovir in United States?

Juan A. Arnaiz is the originator. The local marketing authorisation holder may differ — check the official source linked above.